Sign In
Step 1
Unite with Fellow Investors
Step 2
Choose the Best Attorney
Step 3
Provide Documents
Step 4
Follow Case Progress
Step 5
Get Payout
AKRO.US
id: 1206

Akero Therapeutics (AKRO) Disappointing Drug Trial Results Case

N.D. California
Court
3:24-cv-02534
Case number
13 Sept 2022
Class period Start
09 Oct 2023
Class period End
25 Jun 2024
Lead Plaintiff motion deadline
  • $AKRO stockholder filed a claim vs. Akero Therapeutics for misrepresenteing the SYMMETRY trial, its prospects, and EFX's potential as a NASH treatment.
  • On October 10, 2023, news about the drug trial caused $AKRO to fall 62%, losing $2.1B+ in shareholder value.
  • Affected $AKRO investors may join the claim to be notified about potential recovery.
On October 10, 2023, Akero shared disappointing results from its NASH drug trial.

Results showed no significant improvement in fibrosis or NASH compared to placebo at week 36, with 12 patients discontinuing due to adverse events.

This news caused $AKRO to fall nearly 70% in two days.

Based on these events, $AKRO stockholder filed a claim against Akero and its leaders, accusing them of the following:
  • Around 20% of patients in the SYMMETRY study had cryptogenic cirrhosis without clear NASH.
  • Results from these patients were not considered in measuring NASH resolution.
  • Akero's decision to include these patients could affect the study's outcome and its ability to meet goals.
  • The study didn't follow FDA guidelines as it didn't rule out other causes of cirrhosis in patients.
Considering all the representations, investors have reasons to suspect that Akero misrepresented the SYMMETRY trial, its prospects, and EFX's potential as a NASH treatment.

One of AKRO's investors has already filed a claim vs. Akero Therapeutics in the N. D. of California court.
Case Status
Lead Plaintiff Submission
Alleged Offence
Mismanagement
Misleading Statements
Omissions
Suspected Party
Directors
Management
Security Type
Stocks
Trade Direction
Long
Shock Event Date
10 October 2023
Filing date
26 April 2024
Lead Plaintiff Deadline
25 June 2024
Judge
Yvonne Gonzalez Rogers
Collecting participants…

Akero Therapeutics Inc

Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candid...

    Ticker
    AKRO.US
    ISIN
    US00973Y1082
    CIK
    1744659
    Sector
    Healthcare
    Industry
    Biotechnology
    Country
    USA
    Address
    601 Gateway Boulevard, South San Francisco, CA, United States, 94080